Having a Ball: What Can Be Done About Pediatric Dyslipidemia?
Author: Derek Bagley
On the 20th anniversary of the U.S. Food and Drug Administration’s approval of growth hormone (GH) treatment for idiopathic short stature (ISS), Adda Grimberg, MD, and Colin P. Hawkes, MD, PhD, both of the Children’s Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, published a mini-review in The Journal...
Childhood cancer patients and survivors are at increased risk for growth disturbances, for myriad reasons, and it is important to periodically monitor their growth, according to a paper recently published in The Journal of Clinical Endocrinology & Metabolism. Tomoko Yoshida, MD, PhD, and Angela Delaney, MD, both of St. Jude Children’s Research Hospital in Memphis,...
Liraglutide Increases Insulin Sensitivity Independent of Weight Loss, Study Shows
Liraglutide, the glucagon-like peptide-1 receptor (GLP-1R) agonist used to treat type 2 diabetes and obesity, can lead to rapid improvement in insulin sensitivity, according to a study recently published in Diabetes. “We know that GLP-1R agonists promote weight loss, but we were surprised to find that the GLP-1R agonist liraglutide also has rapid effects on...
The increase in free insulin-like growth factor (IGF)-I levels in prepubertal children with Prader-Willi Syndrome (PWS) treated with exogenous growth hormone (GH) could be caused by increased pregnancy-associated plasma protein A (PAPP-A, PAPP-A2) levels and a reduction in stanniocalcins (STC-1, STC-2), according to a study recently published in The Journal of Clinical Endocrinology & Metabolism....
Word of Honour: John William Honour, PhD, FRCPATH, Discusses His Recent Book on Steroids